Portal de investigación
CCL17 and CCL22 chemokines are upregulated in human obesity and play a role in vascular dysfunction
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Grupos y Plataformas de I+D+i
Abstract
Background/AimsChemokines are known to play critical roles mediating inflammation in many pathophysiological processes. The aim of this study was to investigate the role of chemokine receptor CCR4 and its ligands CCL17 and CCL22 in human morbid obesity. MethodsCirculating levels of CCL17 and CCL22 were measured in 60 morbidly obese patients (mean age, 45 +/- 1 years; body mass index/BMI, 44 +/- 1 kg/m(2)) who had undergone bariatric bypass surgery, and 20 control subjects. Paired subcutaneous (SCAT) and visceral adipose tissue (VCAT) from patients were analysed to measure expression of CCR4 and its ligands by RT-PCR, western blot and immunohistochemical analysis. The effects of CCR4 neutralization ex vivo on leukocyte-endothelial cells were also evaluated. ResultsCompared with controls, morbidly obese patients presented higher circulating levels of CCL17 (p=0.029) and CCL22 (p<0.001) and this increase was positively correlated with BMI (p=0.013 and p=0.0016), and HOMA-IR Index (p=0.042 and p< 0.001). Upregulation of CCR4, CCL17 and CCL22 expression was detected in VCAT in comparison with SCAT (p<0.05). Using the parallel-plate flow chamber model, blockade of endothelial CCR4 function with the neutralizing antibody anti-CCR4 in morbidly obese patients significantly reduced leucocyte adhesiveness to dysfunctional endothelium, a key event in atherogenesis. Additionally, CCL17 and CCL22 increased activation of the ERK1/2 mitogen-activated protein kinase signalling pathway in human aortic endothelial cells, which was significantly reduced by CCR4 inhibition (p=0.016 and p<0.05). ConclusionBased on these findings, pharmacological modulation of the CCR4 axis could represent a new therapeutic approach to prevent adipose tissue dysfunction in obesity.
Copyright © 2023 Hueso, Marques, Morant, Gonzalez-Navarro, Ortega, Real, Sanz and Piqueras.
Datos de la publicación
- ISSN/ISSNe:
- 1664-2392, 1664-2392
- Tipo:
- Article
- Páginas:
- 1154158-1154158
- PubMed:
- 37124725
Frontiers in Endocrinology FRONTIERS MEDIA SA
Citas Recibidas en Web of Science: 8
Documentos
Filiaciones
Keywords
- obesity; adipose tissue; chemokines; inflammation; endothelium; CCL22; CCL17
Financiación
Proyectos y Estudios Clínicos
'Una aproximación translacional desde la clínica a la experimentación animal: Estudio del papel del eje CCL11/CCR3 y la inflamación eosinofílica en la patología cardiovascular asociada a desórdenes metabólicos. -
Investigador Principal: MARIA JESUS SANZ FERRANDO
PROMETEO2019/032 . CONSELLERIA EDUCACION/INNOVACION,UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL/EMPLEO . 2020
CDEI-04/20-A GENT LAURA PIQUERAS (2019/200) CONTRATO
Investigador Principal: LAURA PIQUERAS RUIZ
2019/200C . CONSELLERIA DE SANIDAD
Modulación de la inflamación metabólica en la prevención de la patología cardiovascular: Identificación de nuevas dianas terapéuticas y desarrollo de herramientas farmacológicas novedosas (METINMUNOFAR).
Investigador Principal: MARIA JESUS SANZ FERRANDO
PID2020-120336RB-100 . MINISTERIO DE CIENCIA E INNOVACIÓN . 2021
Cita
Hueso L,Marques P,Morant B,Gonzalez H,Ortega J,Real JT,Sanz MJ,Piqueras L. CCL17 and CCL22 chemokines are upregulated in human obesity and play a role in vascular dysfunction. Front. Endocrinol. 2023. 14. p. 1154158-1154158. IF:3,900. (2).
CCL17 and CCL22 chemokines are upregulated in human obesity and play a role in vascular dysfunction. Hueso L, Marques P, Morant B, Gonzalez H, Ortega J, Real JT, Sanz MJ et al. Frontiers in Endocrinology. 2023 abril 12. 141154158-1154158. DOI:10.3389/fendo.2023.1154158. PMID:37124725.
